The other part of this is pure marketing, OU. The are probably making themselves known to oncologists who had not previously used them.
Hey Bill! Glad to see you on the board, which probably means you've made some good money here. I see posts from Dflawed every once in a while on the MUX board, but that's it. He was such a rabid anti-Obama guy that I stopped following his posts on FB. Glad to hear from you.
If you've been for many years, at least you can smile and look at your profits. I disagree with the premises for selling however, but respect your decision, as this is different for everyone. As I look at the last year, I see the co. manage through a quite uncertain reimbursement environment, drastic overt changes in reimbursement (for the worse), and a sector that, in general, has treaded water because of the reimbursement issues. I have posted before that Steve Jones has held to his philosophy of growing the co. at the fastest possible speed without losing money, and has openly stated, to me at least, that he will forgo profit in exchange for growth, with is exactly what is happening now. The story here is about growth and innovation, and I have also stated before that we will become a REAL player in the sector when revenues come in at $300 million per year. I expect that to happen by 2018, and so long as they continue to grow, I don't give a rat's #$%$ about profit, just don't LOSE money!
Wonder if this is a premise to soften shareholders up so that when McEwen lets go of LA for a pittance (compared to what we want it to be valued for), he'll have ground to stand on.
Funny, 2 posts from me have been removed today, a reply to this idiot was one of them, but the other was reasonable. This gut showing up today is a 100% indicator that we have made a splash.
Hoping for better than that. Historically, we've risen from $1.50 at the start of 2012 to today's high, a better than 3X return. I'm looking for another 3X return in the next 2 year time frame, and, barring big changes in reimbursement, another 2X return between 2016-18 (so, yes, I want to see a share value of $30/share by 2018.) Mgmt is razor sharp, acquisitions, innovations and organic growth have all been excellent! I've not listened to the CC yet (still at work finishing up with my last patient) but reading that mgmt. has been GIVING their new prostate test away to oncologists in return for data is #$%$ BRILLIANT!! You want to establish a need for your product, GIVE IT AWAY AT FIRST!
Old friends, today was NEO's coming out party as far as the stock market is concerned. We are now ON THE MAP. Still a microcap, but its just a matter of time before that changes!
In fact, if the new products were related to HDVY, I think that NEO mgmt. would have to disclose this.
Not sure, but it may have something to do with their alliance. I've posted before that HDVY is nothing more than a shell consisting of several very smart mathematicians and geneticists who have good ideas but couldn't run a company if they had a steering wheel. It is much more likely that Dr. Albitar has come up with his own algorithms for the NextGen sequencing, and we are seeing his genius at work here.
This is classic "old school" mgmt. support of the company's public profile and exposure. Mgmt has been immaculate in their public communication, making sure the market knows EVERYTHING, good and bad about the company's developing business. They are managing this without making any foolish claims or boasts, but also leave no significant news in their pockets when the news is relevant to the business. Well played Bob and Steve!
NEO continues with their development of innovative testing. the NextGen sequencing skillset that they are developing (which is the fastest growing part of their revenue stream) continues to impress and continues to demonstrate their leadership in this space. Here's the headline:
NeoGenomics Expands Next Generation Sequencing Services and Offers 23 Different Profiles for Various Hematologic and Solid Cancers
Company Provides Widest Variety of Actionable Next-Gen Cancer Profiles.
I like the behavior of the trading I'm seeing. I'm not a trader but have observed this type of behavior in the past. We are generating a head of steam and any upside news during the CC and we will test $5 and above. LOVING this!
We are due for some news, either drilling results or other business development. Anything good and we are bound to go up. I am also waiting to see what Argentina does to solve their bond debt problem. They will either come up with something drastic and ugly for business (which I doubt) or will decide on something that is more business friendly. If that happens, all those sideliners will jump in and we will see a nice pop in price.
Love the news, I've wanted to see an acquisition for some time. The cost is nominal and the size is perfect for our co. We get facilities, revenue, Dr.'s and new referrals for a pittance. I'm celebrating the $4.20 close the right way ;)
Yup, something's definitely up. Another million or so after the bell including several blocks over 100K shares. It is a good time for striking business development (unless NeoScore or their genetics evaluation program has gained a license), if so, I hope that it is an acquisition or merger rather than a buyout.
As I posted elsewhere, I don't give a rat's #$%$ about profitability at this point, so long as they keep at break even. I had a conversation (this was about 5 years ago), with the opportunity to speak with Steve Jones when the co. was much smaller (and he answered the phone himself) , and he was CFO and Investor Relations contact. We talked about his mgmt. philosophy. He told me that he had the approach of growing the co. but not at the cost of negative cash flow/profits. He also said (at the time) that any co. growth over 25% YOY would risk having "the wheels fall off" regarding control and quality of the product, and he wanted to see to it that he kept this from happening. Given the co. track record since then, he has stayed true to this philosophy, with only some bumps along the way, created both internally (those old timers here may recall that the co. hired a sales VP that was a disaster) and externally (the Medicare changes as an example.) Steve has shown that his team can manage growth and innovation and they will continue to carve out more and more market share as they go.
While I am firmly committed to this investment, I try to remember that we are still tiny, and that scale is necessary before we truly get the bang from our investment buck. The co. is approaching $100 million/yr revenue, which is a good milestone, but we need to triple that before we become a real player in this space. Given that I've been here since the co. was at $8 million/yr, and the share price was 70 cents/share, I am quite satisfied with the co. execution thus far. If the Russell 3000 is dropping us, I see this as a mindless decision (probably computer algorithm generated) and rare buying opportunity.
Best to all,
Yup! I just found it on the Russell 3000 deletion list as of 6/20/14. Google "Russell 3000 additions and deletions and find it there. Step forward, step back. I say, not a big deal the business will build the value. Actually, a rare buying opportunity, wishing I had more liquid capital and hoping for a pop elsewhere so I can trade some bigger profits out (both of my other big biotech investments are doing quite well but are in need of more consist good news.)
Yags, I posted on Ihub that I've been in since 2007, DCA of 70cents/share and the co. did $8 million/year. We're now at north of $80 million/yr and share price should grow back to the $5-7/share by year's end. From where I stand, this has been a GREAT investment. Let the short-termers and momo investors come and go, we can sit back, make money, and smile!